Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress

Hypertension

Volumn 59, Issue 1, 2012, Pages 151-157

  Kappers, Mariëtte H W ^a   De Beer, Vincent J ^b   Zhou, Zhichao ^b   Danser, A H Jan ^a   Sleijfer, Stefan ^b   Duncker, Dirk J ^b   Van Den Meiracker, Anton H ^a   Merkus, Daphne ^b  

^a Department of Internal Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

endothelin 1; hypertension; oxidative stress; pulmonary hypertension; vascular endothelial growth factor

Indexed keywords

ANTIOXIDANT; ENDOTHELIN; N(G) NITROARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUNITINIB; TEZOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; EXERCISE; HEART FUNCTION; HEART OUTPUT; HYPERTENSION; LUNG CIRCULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REST; SWINE; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD PRESSURE; CORONARY CIRCULATION; ENDOTHELIN-1; FEMALE; HEMODYNAMICS; INDOLES; MALE; MOTOR ACTIVITY; NITRIC OXIDE; OXIDATIVE STRESS; PULMONARY CIRCULATION; PYRROLES; REACTIVE OXYGEN SPECIES; REST; SUS SCROFA; VASOCONSTRICTION;

EID: 83655165286     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.182220     Document Type: Article

References (41)

1. Kappers MH, van Esch JH, Sleijfer S, Danser AHJ, van den Meiracker AH. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens. 2009;27:2297-2309.
2. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019. (Pubitemid 350236338)
3. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204-5212.
4. Dumitrescu D, Seck C, Ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 38:218-220.
5. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol. 2009;297:R1-R5.
6. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol. 1998;274:H1054-H1058.
7. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652-658.
8. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 58:85-92.
9. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14:3470-3476.
10. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 56:675-681.
11. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, Gintant GA. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173-178.
12. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, Wesseling S, Strevens H, Danser AHJ, van den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 58:295-302.
13. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. Nadph oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007;75:702-709. (Pubitemid 47238731)
14. Ruef J, Moser M, Kubler W, Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001;10:311-315. (Pubitemid 34076466)
15. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501. (Pubitemid 30165039)
16. Duncker DJ, Stubenitsky R, Verdouw PD. Role of adenosine in the regulation of coronary blood flow in swine at rest and during treadmill exercise. Am J Physiol Heart Circ Physiol. 1998;275:H1663-H1672.
17. Duncker DJ, Oei HH, Hu F, Stubenitsky R, Verdouw PD. Role of KαATP channels in regulation of systemic, pulmonary, and coronary vasomotor tone in exercising swine. Am J Physiol Heart Circ Physiol. 2001;280:H22-H33.
18. Stubenitsky R, Verdouw PD, Duncker DJ. Autonomic control of cardiovascular performance and whole body O2 delivery and utilization in swine during treadmill exercise. Cardiovasc Res. 1998;39:459-474. (Pubitemid 28346542)
19. Duncker DJ, Stubenitsky R, Tonino PA, Verdouw PD. Nitric oxide contributes to the regulation of vasomotor tone but does not modulate O2-consumption in exercising swine. Cardiovasc Res. 2000;47:738-748.
20. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH, Duncker DJ. Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res. 2003;59:745-754. (Pubitemid 38368691)
21. Hahn SM, Sullivan FJ, DeLuca AM, Bacher JD, Liebmann J, Krishna MC, Coffin D, Mitchell JB. Hemodynamic effect of the nitroxide superoxide dismutase mimics. Free Radic Biol Med. 1999;27:529-535. (Pubitemid 29408638)
22. Johnson ST, Bigam DL, Emara M, Obaid L, Slack G, Korbutt G, Jewell LD, Van Aerde J, Cheung PY. N-Acetylcysteine improves the hemodynamics and oxidative stress in hypoxic newborn pigs reoxygenated with 100% oxygen. Shock. 2007;28:484-490. (Pubitemid 47415261)
23. Liem DA, Manintveld OC, Schoonderwoerd K, McFalls EO, Heinen A, Verdouw PD, Sluiter W, Duncker DJ. Ischemic preconditioning modulates mitochondrial respiration, irrespective of the employed signal transduction pathway. Transl Res. 2008;151:17-26. (Pubitemid 350176680)
24. Simonsen U, Christensen FH, Buus NH. The effect of tempol on endothelium-dependent vasodilatation and blood pressure. Pharmacol Ther. 2009;122:109-124.
25. van der Veldt AA, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJ, van Hinsbergh VW, Smulders YM, Serne EH. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21:439-446.
26. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role for microcirculation. Ann Oncol. 2008;19:927-934. (Pubitemid 351627309)
27. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol Heart Circ Physiol. 1989;256:H126-H131.
28. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267: 16066-16068.
29. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-333. (Pubitemid 40896077)
30. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelina-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058. (Pubitemid 36258731)
31. Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, Reckelhoff JF, Granger JP. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension. 2003;42: 806-810. (Pubitemid 37237329)
32. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J. 2004;45:776-788. (Pubitemid 39545364)
33. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res. 2006;71:226-235.
34. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7:359-371.
35. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol. 2002;137:1021-1030. (Pubitemid 35440742)
36. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098. (Pubitemid 28334007)
37. Stepp DW, Merkus D, Nishikawa Y, Chilian WM. Nitric oxide limits coronary vasoconstriction by a shear stress-dependent mechanism. Am J Physiol Heart Circ Physiol. 2001;281:H796-H803.
38. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 56:1131-1136.
39. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008;29:1936-1948.
40. Dhaun N, Webb DJ. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension. 56:575-577.
41. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol. 2005;3:309-314. (Pubitemid 41264282)